Arkema Stock - weekly review and chemicals sector check

Arkema stock ends the week with a muted performance in a mixed European chemicals sector. Investors now look back at recent newsflow, valuation and sector context after a volatile spell for specialty chemical names.

Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 21:46 CET. Details in the imprint.

Arkema (FR0010313833) is ending this trading week quietly compared with some more volatile European chemicals peers. With no fresh corporate headlines on Friday, the stock trades largely in line with a sector that has struggled to gain clear direction in recent sessions.

How Arkema stock ended the week

Arkema shares have traded in a relatively tight range this week, with only modest day-to-day moves against a backdrop of cautious sentiment in European cyclicals. The stock remains some distance below its 52-week high, reflecting lingering macro and demand uncertainty.

The 52-week trading range for Arkema currently spans roughly from EUR 48.30 on the downside to around EUR 67.05 on the upside, underlining how volatile the past year has been for the name. Overall, the week’s muted close suggests investors are waiting for clearer fundamental catalysts.

Position in the chemicals peer group

Within the European chemicals universe, Arkema is often compared with specialty players such as Clariant, Evonik and Covestro, all facing similar questions on demand visibility and pricing power. Recent sector performance has been mixed, with some peers more sensitive to energy and feedstock swings.

Grossly speaking, Arkema’s valuation remains in a mid-pack position in its peer group, with the stock trading at a discount to some high-growth specialty names but at a premium to more commodity-heavy producers. That positioning mirrors its hybrid portfolio between high-performance materials and more cyclical intermediates.

What analysts currently say

Consensus data compiled by Investing.com show that around 16 analysts cover Arkema, with an overall rating leaning toward "Buy". According to that breakdown, 7 recommend buying the stock, 6 advise holding and 3 suggest selling at current levels.

The same consensus places the average 12-month price target near EUR 63.63 per share, with estimates stretching from about EUR 50.00 on the low end to EUR 83.00 at the top. That average target implies close to a 10% upside potential versus the latest quoted price.

Earnings calendar and next catalysts

Arkema’s investor relations page lists regular quarterly publications and capital markets days but did not flag a new earnings date on Friday beyond the already scheduled financial calendar. The next set of detailed numbers remains a key potential catalyst for any shift in the stock’s direction.

Until that update, investors are likely to focus on sector data points such as order trends in construction, automotive and packaging, all important end-markets for Arkema’s advanced materials and coatings businesses. Any signs of demand stabilization there could gradually filter into expectations for the stock.

How the company makes money

Arkema generates revenue mainly from specialty materials such as adhesives, advanced coatings, high-performance polymers and acrylics that go into construction, automotive, electronics and consumer goods applications. The portfolio also includes intermediate chemicals, though management has steadily pushed the mix toward higher-margin, lower-volatility specialties.

Where the stock trades today

Arkema shares (FR0010313833) trade on Euronext Paris at around EUR 57.90 as of 06/19/2026, 17:35 CET.

Arkema at a glance

• Company: Arkema S.A.
• ISIN: FR0010313833
• WKN: A0ML38
• Ticker: AKE
• Venue: Euronext Paris
• Price (as of 06/19/2026, 17:35 CET): 57.90 EUR
• Market cap: 7,800,000,000 EUR (as of 06/19/2026)
• Sector / Industry: Materials / Specialty Chemicals
• Index membership: SBF 120
• Next earnings date: not officially scheduled

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.